Real-world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients.
Tasaki Y, Ito N, Mimura Y, Sugiyama Y, Ogawa R, Shimura T, Nakamura M, Kawakita D, Hamamoto S, Uemura T, Yokota K, Iida M, Odagiri K, Kimura Y, Hotta Y, Komatsu H, Okuda K, Niimi A, Yasui T, Iwasaki S, Morita A, Kataoka H, Takiguchi S, Furukawa-Hibi Y.
Tasaki Y, et al. Among authors: sugiyama y.
Asia Pac J Clin Oncol. 2024 Apr 29. doi: 10.1111/ajco.14073. Online ahead of print.
Asia Pac J Clin Oncol. 2024.
PMID: 38682421